## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.3% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($135.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Q3 Earnings Outperformers: Agilent (NYSE:A) And The Rest Of The Research Tools & Consumables Stocks**
- Source: Finviz | 20251210T110722 | Neutral | Relevance: 98%
- This article reviews the Q3 earnings performance of companies in the research tools & consumables industry. It highlights Agilent (NYSE:A) as a top performer with 9.4% year-on-year revenue growth, while also detailing the performances of Sotera Health Company (NASDAQ:SHC), Avantor (NYSE:AVTR), Danaher (NYSE:DHR), and Bio-Techne (NASDAQ:TECH). The sector overall experienced mixed results with revenues beating estimates by 1.1% but next quarter's guidance falling 1.3% below expectations.

**2. Goldman Sachs Initiates Coverage on Agilent (A) with Positive Outlook**
- Source: GuruFocus | 20251209T210814 | Bullish | Relevance: 98%
-  Goldman Sachs has initiated coverage on Agilent Technologies (A) with a "buy" rating and a price target of $170, anticipating a 19% upside. The investment bank expects Agilent to benefit from a biopharma instrument replacement cycle, industrial sector recovery, and the upcoming launch of the Infinity III HPLC. This positive outlook is supported by Agilent's consistent financial performance, strong market position, and solid financial health.

**3. Here Are Tuesday's Top Wall Street Analyst Research Calls: Agilent, Alibaba, Delta Air Lines, Intel, JD.com, Micron Technology, Reddit and More**
- Source: 24/7 Wall St. | 20251209T131700 | Somewhat-Bullish | Relevance: 91%
-  This article details top Wall Street analyst upgrades, downgrades, and initiations from December 9, 2025, covering several major companies. It also provides a market overview for pre-market futures, Treasury bonds, oil and gas, gold, and cryptocurrency, highlighting investor anticipation of a potential Federal Reserve rate cut. The market saw stocks decrease across the board on Monday, with major indices closing negatively due to Federal Reserve uncertainty.

**4. Microplate Systems Market Is Booming So Rapidly| Thermo Fisher Scientific; Danaher Corporation; Agilent Technologies Inc; PerkinElmer Inc**
- Source: www.pharmiweb.com | 20251209T104949 | Bullish | Relevance: 90%
- The global microplate systems market is projected to grow at a CAGR of approximately 4%, driven by increased R&D spending, rising incidence of chronic diseases, and the adoption of multi-mode readers. Despite growth drivers, high costs and a shortage of skilled personnel remain significant barriers. Key players like Thermo Fisher Scientific and PerkinElmer are enhancing system performance and flexibility through technological advancements and strategic initiatives.

**5. Astrotech Bets On Mass Spec Innovations Despite Steep Losses**
- Source: Finimize | 20251210T021106 | Neutral | Relevance: 63%
-  Astrotech Corporation (NASDAQ: ASTC), a micro-cap tech incubator, is banking on its mass spectrometry technology to drive future growth, despite currently facing significant financial losses and cash burn. The company focuses on commercializing AMS Technology through subsidiaries like 1st Detect (explosives/narcotics detection) and AgLAB (hemp/cannabis industries), and is developing new ventures in breath analysis and environmental testing. While Astrotech boasts unique technology and potential in emerging markets, it faces challenges including thin revenue, stiff competition, and a high risk of shareholder dilution due to ongoing operating losses.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 21.8x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.5B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 21.8 |
| Current P/E | 24.0 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 9.3pp (needs >4.0% for momentum thesis). AM_20 at -3.2% indicates price below own 20MA trend. Underperforming sector by 3.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.15x) but short-term weakness (below SMA20). MACD histogram bearish (-1.33), momentum weakening. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.32% (CS: 9) | Weak |
| RSI_14 | 43.4 | Neutral |
| MACD Histogram | -1.33 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 1.152x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $142.87
- **Stop Loss:** $135.35 (5.3% risk)
- **Target:** $150.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 183
- **Position Value:** $26,145.21
- **Portfolio %:** 26.15%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*